All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antibody therapeutics
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Casdin Capital
Deal Size: $25.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 29, 2020
Details:
The Series A Financing positions the company for rapid scaling of its novel platform and advancing its portfolio of innovative antibody therapeutics for veterinary use.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim Venture Fund
Deal Size: $29.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 23, 2020
Details:
The company’s therapeutic platform is uniquely positioned to discover and develop novel small molecule drugs that can both increase autophagy to more rapidly clear toxic proteins and attenuate the production of neurotoxic proteins.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mitochondria therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Axil Capital Partners
Deal Size: $9.8 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 01, 2020
Details:
LUCA Science is developing an innovative platform of highly functional mitochondrial using proprietary technologies. LUCA Science’s mitochondria can be stored and delivered as a biopharmaceutical agent.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ADX10061
Therapeutic Area: Neurology Product Name: ADX10061
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Innosuisse
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Funding August 27, 2020
Details:
CHF600K Innosuisse grant will support SIB's computational approaches to identify new therapeutic indications for ADX10061, a potent and selective dopamine D1 receptor antagonist.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: The Column Group
Deal Size: $73.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 29, 2020
Details:
Nura Bio seeks to alter the course of neurological disease by targeting the fundamental pathways underlying axon degeneration and neuroimmune regulation to preserve neuronal integrity.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Orexia Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 22, 2020
Details:
After successfully reaching this development milestone in the collaboration, Orexia exercised an option to exclusively license the orexin receptor type 2 (OX2R) program from X-Chem, which comprises multiple novel OX2R-specific small molecule orexin positive modulators.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Monoclonal Antibodies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Invetx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 16, 2020
Details:
The proprietary platform combines industry-leading technologies from partners AbCellera, Twist Bioscience and WuXi Biologics to develop fully species-specific, optimized and half-life-extended monoclonal antibodies (mABs) for veterinary use.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Exosome-mediated RNAi
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
The recently issued US patent provides broad coverage for pharmaceutical compositions comprising exosomes containing nucleic acid-based therapeutics, such as RNAi agents and antisense oligonucleotides, which have been loaded by electroporation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: BioArctic AB
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 29, 2020
Details:
BioArctic AB and University of Oslo, Institute of Clinical Medicine have signed a research collaboration agreement to increase the understanding of Apolipoprotein E (ApoE) as a drug target for Alzheimer's disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RNA interference
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,230.0 million Upfront Cash: $20.0 million
Deal Type: Licensing Agreement June 09, 2020
Details:
During this research collaboration and five-target license agreement, Evox will be responsible for exosome engineering in order to achieve brain/CNS-targeting, drug loading and analytics and some in vitro assay development, as well as material supply for initial in vivo studies.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
